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Abstract: Cardiovascular disease (CVD) remains a major cause of premature death in patients with chronic kidney dis-
ease (CKD), including renal transplant recipients. Both interplay of traditional cardiovascular and renal specific risk fac-
tors have been shown to be associated with an increased risk of cardiovascular death in patients with CKD. Recently, 
there has been great interest in the role of novel biomarkers, in particular adiponectin and leptin, and its association with 
CVD in the CKD population. Adiponectin is a multifunctional adipocyte-derived protein with anti-inflammatory, anti-
atherogenic and insulin sensitizing activity. Recent observational studies have shown adiponectin to be a novel risk 
marker of CVD in patients with stages 1 to 5 CKD. Leptin is an adipocyte-derived hormone that promotes weight loss by 
decreasing food intake. Similarly, there are observational studies to support an association between leptin and CVD, in-
cluding patients with CKD. In the CKD population, leptin may be associated with uremic cachexia and subsequent in-
creased mortality. This review aims to summarize the pathophysiological and potential clinical roles of these cardiovascu-
lar biomarkers in patients with CKD. 
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INTRODUCTION 
  Cardiovascular disease (CVD) remains the major cause 
of premature death in patients with chronic kidney disease 
(CKD). CKD increases the risk of cardiac death 10-20 fold 
compared to the non-CKD population despite stratification 
for age, sex, race and diabetes [1, 2]. The two predominant 
clinical presentations of CVD in CKD are left ventricular 
hypertrophy (LVH) and coronary artery disease (CAD) [3]. 
Furthermore, the risk of cardiovascular disease and cardiac 
death rises significantly with glomerular filtration rate (GFR) 
under 60mls/min and is incremental with further declines in 
kidney function [4, 5]. In fact, the majority of patients with 
CKD die from CVD prior to reaching end stage kidney dis-
ease (ESKD) [6]. Both an interplay of traditional cardiovas-
cular and renal specific risk factors (anemia, oxidative stress, 
inflammation, hyperhomocysteinemia) have been shown to 
be associated with an increased risk of cardiovascular death 
in patients with CKD. Despite, the negative impact of CVD 
in patients with CKD, various randomized controlled studies 
have either excluded patients with kidney disease or have 
failed to show any benefit in the treatment of either tradi-
tional or renal specific risk factors on cardiovascular out-
come [7-9]. In addition, recent epidemiological studies have 
shown obesity and the metabolic syndrome to be independ-
ent predictors for CKD and progression to ESKD [10, 11]. 
As such, there has been a growing interest in the role of 
novel biomarkers and its association with CVD in patients 
with CKD, in particular the adipokines adiponectin and 
leptin. This review aims to summarize the pathophysiologi-
cal and potential clinical role of these adipokines in patients 
with CKD.  
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ADIPONECTIN 
  In recent years, there has been a greater appreciation of 
adipose tissue as an active metabolic organ beyond a storage 
depot for triglycerides, including the secretion of various 
adipokines, such as adiponectin and leptin. Human adi-
ponectin is a multifunctional adipocyte-derived protein with 
anti-inflammatory, anti-atherogenic and insulin sensitizing 
activity [12]. It is the most abundant adipocyte-derived pro-
tein, with a collagenous N-terminal and a globular carboxyl 
terminal with sequence homology to the C1q family of com-
plement proteins and collagen X and VIII. It circulates in 
low, medium and high molecular weight forms with clinical 
data indicating that the high molecular weight form most 
strongly correlates with improved insulin sensitivity and 
glucose tolerance as well as having protective anti-
atherosclerotic effects [13, 14]. Adiponectin levels have been 
shown to be lower in males, obesity, insulin resistance (in-
cluding metabolic syndrome), type 2 diabetes mellitus, coro-
nary artery disease and essential hypertension [15-18]. In 
contrast, CKD is associated with hyperadiponectinemia in-
cluding nephrotic syndrome [19]. This is more pronounced 
with more severe CKD, such that end-stage kidney disease 
patients have serum adiponectin levels up to three times 
higher than those in the normal population [20]. The rise in 
adiponectin with declining glomerular filtration rate (GFR) 
has been postulated to be related to impaired renal elimina-
tion or metabolism, though the exact role of the kidney in the 
biodegradation and excretion of adiponectin remains unclear.  
The Role of Adiponectin as a Cardiovascular Risk Factor 
in Chronic Kidney Disease 
  Hypoadiponectinemia predicts the development of CVD 
in the non-CKD population. For example, longitudinal fol-
low-up of male patients with type II diabetes showed that 
those with the highest quintile of adiponectin compared to 
the lowest quintile had a lower risk of developing CAD and 288 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Kaisar et al.
myocardial infarction, independent of other variables [21]. 
Recent observational studies have shown adiponectin to be a 
novel risk marker of CVD in patients with stage 1 to 5 CKD. 
These prospective studies have revealed that hypoadiponecti-
nemiapredicts the development of new cardiovascular events 
in patients with CKD, including the hemodialysis popula-
tion. The inverse relationship between adiponectin, GFR and 
CVD in patients with CKD suggests a protective role for 
adiponectin against the development of cardiovascular 
events in this patient population. This association has been 
highlighted in several recent studies. Zoccali et al. showed 
that in their cohort of 227 hemodialysis patients who were 
followed for a mean of 31±13 months that each 1 g/mL 
increase in adiponectin concentration was associated with a 
3% risk reduction in new cardiovascular events [22]. The 
relative risk of adverse cardiovascular events was 1.56 times 
(95% confidence interval, 1.12 to 1.99 times) higher among 
patients in the first adiponectin tertile, compared with those 
in the third tertile. In this study, higher adiponectin levels 
predicted lower cardiovascular events in the hemodialysis 
patients independent of other variables. Analogous results 
have been observed in a study by Becker et al., from the 
Mild to Moderate Kidney study database in non-diabetic 
subjects with primarily stage 3 to 4 CKD [measured GFR 
between 38 and 96mls/min] [23]. At a median follow-up of 
54 months, patients who developed new cardiovascular 
events had significantly lower adiponectin levels (odds ratio, 
0.72; 95% CI 0.58 to 0.89; P=0.002). Further corroborating 
evidence for this link has been provided in a recently pub-
lished study by Iwashima et al., who followed 150 patients 
with CKD prospectively for a mean period of 32 months 
[24]. Adiponectin levels were significantly higher in patients 
with more severe kidney impairment as assessed by CKD 
stage. After dividing the patients into a high and low group 
based upon gender-specific median values of adiponectin, 
the low adiponectin group had a significantly shorter event-
free survival compared to the higher group (<4.39 g/ml in 
men, <6.84 g/ml in women, P<0.03). Using multivariate 
Cox proportional hazards model analysis, each 1 g/ml in-
crease in adiponectin was associated with a 14% decrease in 
the risk of CVD (adjusted hazard ratio 0.86, 95% CI 0.75 to 
0.96, P= 0.004). Furthermore, adiponectin may be predictive 
of future ischemic cardiac events, as patients with previous 
IHD (n = 65), had a significantly shorter IHD-free survival 
in the lower adiponectin group (<4.45 g/ml in men, <4.49 
g/ml in women, P<0.05). In addition, the percentage of the 
high-molecular-weight form of adiponectin in patients with 
severe CKD and IHD during follow-up was significantly 
smaller than that in those without IHD (P<0.02).  
  In contrast to the above findings, Menon et al., in their 
analysis of 820 patients with a GFR range of between 13 and 
55 mls/min from the MDRD (Modified Renal Diet) database 
revealed a direct correlation between adiponectin and the 
relative risk of cardiovascular mortality [25]. In multivari-
able adjusted Cox models, a 1 g/ml increase in adiponectin 
was associated with a 3% (hazard ratio 1.03; 95% CI 1.01 to 
1.05; P=0.02) elevated risk for all-cause and 6% (hazard 
ratio 1.06; 95% CI 1.03 to 1.09; P=0.001) higher risk for 
cardiovascular mortality. In view of the strong association 
between CKD and CVD, the direct correlation between adi-
ponectin and CVD in the MDRD study may be due to a re-
sidual confounding effect of reduced renal function or proc-
esses accompanying CKD, but unadjusted for reduced GFR. 
For example, the mean GFR and adiponectin in the MDRD 
study was 32 mls/min and 6 mol/L respectively, in com-
parison to 63 mls/min and 12 mol/L correspondingly in the 
study by Becker et al., highlighting the strong association 
between adiponectin and GFR [20]. Furthermore, in a recent 
study involving hemodialysis patients who underwent coro-
nary artery stenting for ischemic heart disease, only adi-
ponectin in multiple logistic regression analysis was shown 
to be associated with increased in-stent restenosis with an 
odds ratio for restenosis of 0.651 (P=0.001, 95% confidence 
interval: 0.506–0.839) with each 1 g/ml increase in plasma 
adiponectin concentration [26]. In this study, lower adi-
ponectin levels predicted increased in-stent restenosis. 
Mechanism of Adiponectin Cardiovascular Protection 
  While the above observational studies have linked adi-
ponectin to improved cardiovascular outcomes in patients 
with CKD, it remains unclear as to how adiponectin confers 
vascular protective benefits. However, there is now evolving 
evidence of its mechanistic actions that may account for its 
cardioprotective benefits. 
  Adiponectin is an abundant protein hormone, comprising 
nearly 0.01% of all plasma proteins [27]. Exclusively se-
creted by adipocytes, it possesses anti-inflammatory, anti-
atherogenic and beneficial metabolic actions. Adiponectin 
improves insulin sensitivity by inhibiting hepatic glu-
coneogenesis and increased glucose uptake via translocation 
of the insulin responsive glucose transporter (GLUT4) to the 
cell surface in skeletal muscle cells [28]. Hypoadipon-
ectinemia is also associated with dyslipidemia, in particular 
elevated triacylglycerol rich lipoproteins, a common feature 
of obesity related dyslipidemia. In humans including healthy 
adults and subjects with type 2 diabetes, adiponectin has 
been shown to be positively correlated to high density lipo-
proteins and inversely related to triglycerides (TG), very low 
density lipoproteins and low density lipoproteins [29-31].
Adiponectin may have a direct effect on improving dyslipi-
demia, particularly in obesity. In animals, administration of 
adiponectin to lipodystrophic and obese mice has been 
shown to reduce TG and free fatty acid levels [32]. 
  Furthermore, adiponectin is inversely related to various 
inflammatory markers such as tumour necrosis factor-
(TNF-), C-reactive protein (CRP) and interleukin-6 (IL-6) 
in normal subjects and patients with type 2 diabetes and 
CVD [33-35]. In addition, adiponectin has also been shown 
to exhibit anti-inflammatory activity in atherosclerotic ex-
perimental models including reduction in TNF- production 
[36, 37]. Inflammatory markers are typically elevated in 
CKD and are predictive of cardiovascular events in this 
population. It is unclear if higher adiponectin levels in kid-
ney failure represents a compensatory process to the inflam-
matory milieu in the CKD, as other unknown variables, par-
ticularly associated with uremia may confound this associa-
tion. While direct anti-inflammatory actions may benefit the 
vasculature in CVD, there is evolving evidence for direct 
anti-atherogenic actions of adiponectin. The hallmark of 
atherosclerosis is proliferation and migration of vascular 
smooth muscle cells (VSMC). In experimental models, adi-
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mitogen-activated protein kinase and other growth factors 
capable of stimulating smooth muscle synthesis including 
platelet derived growth factor and fibroblast growth factor 
[38]. Adiponectin has also been shown to increase produc-
tion of nitric oxide and tissue inhibitor of metalloproteinase-
1, resulting in vasodilatation and decrease in plaque rupture, 
respectively [38, 39].
  While most studies to date point to a consistent link be-
tween lower adiponectin levels and CVD in patients with 
CKD, there are no interventional studies to demonstrate any 
benefit in increasing adiponectin levels on cardiovascular 
outcome in this group. Several studies in non-CKD patients 
have demonstrated increased adiponectin levels with weight 
loss, physical exercise and the use of pharmacological 
agents, including angiotensin converting enzyme inhibitors, 
angiotensin 2 receptor blockers, statins and thiazolidinedi-
ones [40-42]. Similarly, there have been two studies demon-
strating increased adiponectin levels with the use of ramipril 
and candersartan in type 2 diabetics with proteinuria and 
normal kidney function and patients on peritoneal dialysis, 
respectively [43, 44]. However, to date, there have been no 
studies that have investigated the prognostic impact of in-
creasing adiponectin levels on cardiovascular morbidity and 
mortality, regardless of the absence or presence of kidney 
disease. 
LEPTIN 
  In contrast to studies which have consistently found a 
strong inverse association between adiponectin and CVD, an 
association between leptin and CVD has been less clearly 
demonstrated. Leptin, a 16kDA protein is a product of the 
obesity (ob) gene, which is secreted by white adipose tissue 
and primarily bound to protein in lean adults [45]. Leptin 
forms part of the IL-6 family of pro-inflammatory cytokines 
and is principally cleared from the circulation by the kidney 
via a combination of glomerular filtration and subsequent 
tubular degradation [46]. Leptin levels are elevated in pro-
portion to insulin levels, glucocorticoids, cytokines and par-
ticularly obesity [47]. Leptin is anorectic and in normal hu-
mans functions to decrease appetite and in mice also in-
creases energy expenditure. Similar to adiponectin, there has 
been a great interest in the role of leptin in CVD. In contrast 
to adiponectin, leptin levels are inversely related to body fat 
mass [48]. The inability of leptin to induce weight loss in 
this instance is presumed to be related to leptin resistance. 
Leptin exerts its anorectic effects via the hypothalamus. 
Leptin binds to the b isoform of the obesity receptor (Ob-Rb) 
and increases the synthesis of proopiomelanocortin via the 
Janus-activated kinase (JAK) and signal transducers and 
activators of transcriptions (STAT) pathway. Proopiomela-
nocortin is subsequently converted to -melanocyte-stimu-
lating hormone, which in turn activates melanocortin-3 and -
4 receptors to decrease appetite [49]. Furthermore, leptin 
antagonizes the actions of the appetite stimulating hormone, 
neuropeptide Y, and the inhibitory effects of Agouti-related 
protein on melanocortin-3 and -4 receptors signaling path-
ways [50]. The exact role of leptin resistance is ill-defined 
but postulated mechanisms include elevated suppressors of 
the cytokine signaling family (SOCS3) levels (which results 
in negative feedback inhibition of the JAK-STAT pathway), 
decreased transport of leptin via saturable transport pathways 
across the blood brain barrier to the arcuate nucleus, and 
possibly protein tyrosine phosphatase 1B inhibition of JAK 
phosphorylation [51-53]. Whether leptin resistance exists in 
CKD remains unknown.  
Evidence for Leptin as a Cardiovascular Risk Factor 
  Experimental studies suggest a role for leptin as a causa-
tive or contributing factor in the pathogenesis of atheroscle-
rosis. Leptin’s proatherogenic effects include the develop-
ment of hypertension, oxidative stress, endothelial dysfunc-
tion, inflammation, platelet aggregation, migration, prolifera-
tion and hypertrophy of VSMC. There has been particular 
interest in the role of leptin in obesity related hypertension. 
While obesity is associated with central hypothalamic resis-
tance, this phenomenon appears to be selective primarily to 
its anorectic effect. Chronic hyperleptinemia has been shown 
to be associated with activation of the sympathetic nervous 
system (SNS) via both central (despite central hypothalamic 
resistance) and possibly peripheral mechanisms. Elevated 
leptin levels, either in transgenic mice with hyperleptinemia 
or by prolonged exogenous administration of leptin, resulted 
in elevated mean arterial pressure by 10-20mmHg. Admini-
stration of -blockers abolished leptin-induced hypertension, 
supporting a role for the SNS in the development of hyper-
tension [54, 55]. The stimulatory effect of leptin on the SNS 
is likely a predominant central effect as transection of distal 
sympathetic fibers failed to abrogate the hypertensive re-
sponse [56]. Furthermore, the hypertensive effect of leptin 
was abolished completely after selective excision of the hy-
pothalamic arcuate nucleus [50]. Leptin has also been shown 
to directly increase catecholamine production in the adrenal 
medulla [57]. Additionally, leptin may have direct functional 
and structural renal consequences in obesity. Acute admini-
stration of leptin in rats results in natriuresis and saliuresis 
independent of GFR, renal blood flow and potassium excre-
tion, an effect that was blunted by blockade of the renal SNS 
[58, 59]. Of interest, obese rats experienced a diminished 
diuretic effect in response to leptin [58]. Clinical studies 
suggest an association between leptin and hypertension. 
Leptin has been shown to be linked to mean blood pressure 
in lean subjects with essential hypertension [60]. In addition, 
there was a strong positive correlation between serum leptin 
and renal sympathetic activation in men with varying levels 
of adiposity [61]. However, to date there have been no simi-
lar studies in the CKD population. 
  Observational data support an association between leptin 
and CVD. Elevated leptin levels have been shown to be as-
sociated with early markers of CVD, including increased 
carotid intima media thickness (IMT) and decreased arterial 
distensibility [62, 63]. However, other studies have failed to 
discover a similar association between leptin and carotid 
IMT [64, 65]. Several studies have highlighted an associa-
tion between hyperleptinemia and coronary artery disease in 
various patient populations, including patients with type 2 
diabetes and those with hypertension [66-68]. The best evi-
dence to date for leptin’s proatherogenic role comes from the 
West of Scotland Coronary Prevention Trial (WOSCOPS) 
[69]. The WOSCOPS study was designed to determine the 
efficacy of pravastatin in the prevention of ischemic heart 
disease in men with moderate hypercholesterolemia. In this 
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follow-up, elevated leptin levels predicted the development 
of new coronary events independent of body mass index and 
inflammation. Each 1 standard deviation increase in leptin 
concentrations was associated with a 25% increased relative 
risk of an event (odds ratio 1.25, 95% confidence interval 
[CI], 1.10 to 1.43; P<0.001). Increased plasma leptin has also 
been shown to predict the development of cardiac failure and 
is positively associated with the severity of left ventricular 
hypertrophy [70, 71]. Hyperleptinemia is also an independ-
ent predictor of acute ischemic and hemorrhagic strokes [72, 
73].  
Putative Mechanisms for Leptin-Induced CVD  
  Experimental studies have provided an insight into the 
potential mechanistic basis for leptin’s proatherogenic ef-
fects. Hyperleptinemia, via up regulation of nitric oxide pro-
duction, resulted in the generation of reactive oxygenation 
species (ROS). Various studies have shown that leptin-
treated mice have elevated levels of various markers of oxi-
dative stress, including malonyldialdehdye, peroxides, iso-
prostanes and oxidized lipoproteins, a hallmark feature of 
atherosclerosis, as well as reduction in anti-oxidant mole-
cules, such as glutathione [74-76]. Leptin may also promote 
endothelial dysfunction, though this remains controversial. 
The data are conflicting on the potential benefits of leptin-
induced nitric oxide (NO) generation and subsequent vaso-
dilatation versus the possible generation of ROS from ele-
vated NO levels [77, 78]. Similar contradictory results have 
been surmised from clinical studies on the association be-
tween leptin, NO and endothelial function, and thus at pre-
sent the role of leptin remains unclear [65, 79]. Leptin is also 
associated with increased platelet reactivity and aggregation, 
enhanced immune function, cardiac hypertrophy, and im-
paired cardiac contractility [80-83]. 
The Role of Leptin in Chronic Kidney Disease 
  There are sparse and conflicting data on leptin in CKD, 
particularly its association with CVD and mortality. In gen-
eral, leptin levels are significantly higher in patients on di-
alysis, particularly those on peritoneal dialysis, compared to 
the non-dialysis population [84-86]. This may simply reflect 
the role of the kidney in the filtration and subsequent tubular 
degradation of leptin [87]. However, other variables have 
been shown to affect leptin levels in CKD patients. Teta et
al. showed that metabolic acidosis reduced the release of 
leptin from adipose tissue [88]. In addition, uremia reduces 
leptin gene expression in adipocytes, which may reflect a 
compensatory mechanism from decreased elimination [89]. 
In contrast, endotoxins and inflammation in kidney failure 
have been shown to up regulate leptin production [90]. 
While some of the previous studies have not reported a cor-
relation between leptin and body mass index, leptin has been 
shown to be correlated with body fat mass using dual energy 
x-ray absorptiometry (DEXA) in stage 5 CKD patients [91]. 
Higher leptin levels correlated with elevated lipid concentra-
tion (cholesterol and triglycerides), left ventricular hypertro-
phy and lower clinical atherosclerosis score in a study in-
volving peritoneal dialysis patients [92]. Leptin has also been 
shown to be significantly correlated with higher ejection 
fraction in a group of hemodialysis patients [93]. To date, the 
largest prospective study of leptin in CKD subjects involved 
71 hemodialysis patients with a mean follow up period of 83 
months [94]. During the study, 48 (63%) patients died, pre-
dominantly due to CVD (67%) and infection (21%). While 
lower leptin levels were significantly associated with all 
cause mortality, baseline serum leptin concentrations were 
also significantly lower in patients who died from CVD (4.7 
± 9.4 g/L, P<0.05) or infections (4.0 ± 2.7 g/L, P<0.05). 
These studies support a role for leptin in the increased car-
diovascular mortality of patients with severe kidney failure. 
The majority of experimental work has shown a positive 
correlation between leptin and pro-atherogenic effects, 
whereas an adverse cardiovascular profile in CKD patients in 
the clinical setting has been attributed to lower levels of 
leptin. The exact cause for this discrepancy is unknown but 
low levels of leptin may reflect a state of malnutrition, and 
hence contribute towards uremic cachexia. Leptin levels are 
higher in healthier dialysis subjects, and are directly corre-
lated with improved markers of nutrition [92, 95, 96]. Con-
versely, other studies have reported an inverse relationship 
between higher levels of leptin and nutritional markers in 
CKD [91]. In addition, leptin may function as a negative 
acute response phase protein. In stage 5 CKD patients, CRP 
was inversely related to negative acute phase proteins, in-
cluding albumin, transferrin and leptin [95]. However, CRP 
has also been shown to be positively correlated with leptin in 
CKD [96]. These clinical studies underscore the difficulty in 
elucidating the role of leptin in the pathogenesis of CVD in 
CKD amongst the meshwork of other contributing factors to 
the CVD burden in this patient population, including nutri-
tion, inflammation and conventional cardiovascular risk fac-
tors. 
CONCLUSION 
  Patients with CKD remain at high risk of premature car-
diovascular death. Interventional studies addressing tradi-
tional cardiovascular risk factors in this group of patients 
have failed to yield significant benefits. As such, there has 
been great interest in alternative cardiovascular risk factors 
including adipokines. While there has been a preponderance 
of observational and experimental data linking adipokines to 
CVD in the CKD and non-CKD population, their exact role 
remains to be verified. The interplay of other variables asso-
ciated with uremia further adds to the complexity in deter-
mining whether adipokines have significant pro atherogenic 
properties in CKD. Adipokines like leptin and adiponectin 
may serve as biomarkers of CVD in CKD. To date, there 
have been no interventional studies with either adiponectin 
or leptin on cardiovascular outcomes in the humans, includ-
ing those with CKD. In conclusion, further studies are neces-
sary to clarify and determine the role of adipokines in CVD 
in CKD, either as a biomarker or potential therapeutic tool in 
addressing the cardiovascular burden in CKD.  
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